Pathogenesis of Aspergillus fumigatus and the Kinetics of Galactomannan in an In Vitro Model of Early Invasive Pulmonary Aspergillosis: Implications for Antifungal Therapy

Hope, William W.; Kruhlak, Michael J.; Lyman, Caron A.; Petraitiene, Ruta; Petraitis, Vidmantas; Francesconi, Andrea; Kasai, Miki; Mickiene, Diana; Sein, Tin; Peter, Joanne; Kelaher, Amy M.; Hughes, Johanna E.; Cotton, Margaret P.; Cotten, Catherine J.; Bacher, John; Tripathi, Sanjay; Bermudez, Louis; Maugel, Timothy K.; Zerfas, Patricia M.; Wingard, John R.
February 2007
Journal of Infectious Diseases;2/1/2007, Vol. 195 Issue 3, p455
Academic Journal
Background. Little is known about the pathogenesis of invasive pulmonary aspergillosis and the relationship between the kinetics of diagnostic markers and the outcome of antifungal therapy. Methods. An in vitro model of the human alveolus, consisting of a bilayer of human alveolar epithelial and endothelial cells, was developed. An Aspergillus fumigatus strain expressing green fluorescent protein was used. Invasion of the cell bilayer was studied using confocal and electron microscopy. The kinetics of culture, polymerase chain reaction, and galactomannan were determined. Galactomannan was used to measure the antifungal effect of macrophages and amphotericin B. A mathematical model was developed, and results were bridged to humans. Results. A. fumigatus penetrated the cellular bilayer 14-16 h after inoculation. Galactomannan levels were inextricably tied to fungal invasion and were a robust measure of the antifungal effect of macrophages and amphotericin B. Neither amphotericin nor macrophages alone was able to suppress the growth of A. fumigatus; rather, the combination was required. Monte Carlo simulations showed that human dosages of amphotericin B of at least 0.6 mg/kg were required to achieve adequate drug exposure. Conclusions. This model provides a strategy by which relationships among pathogenesis, immunological effectors, and antifungal drug therapy for invasive pulmonary aspergillosis may be further understood.


Related Articles

  • Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Clemons, Karl V.; Stevens, David A. // Medical Mycology;Feb2006, Vol. 44 Issue 1, p69 

    Mortality from invasive pulmonary aspergillosis approaches 80% with few useful therapeutic options available. In these studies, we examined the efficacy of micafungin (MICA) alone or in combination with other antifungals in a model of pulmonary aspergillosis in immunosuppressed DBA/2 mice...

  • Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: Synergistic Interaction between an Antifungal Triazole and an Echinocandin. Petraitis, Vidmantas; Petraitiene, Ruta; Sarafandi, Alia A.; Kelaher, Amy M.; Lyman, Caron A.; Casler, Heather E.; Sein, Tin; Groll, Andreas H.; Bacher, John; Avila, Nilo A.; Walsh, Thomas J. // Journal of Infectious Diseases;6/15/2003, Vol. 187 Issue 12, p1834 

    Invasive pulmonary aspergillosis is an important cause of morbidity and mortality in immunocompromisedpatients. Simultaneous inhibition of fungal cell-wall and cell-membrane biosynthesis may result in synergistic interaction against Aspergillus fumigatus. We studied the antifungal activity of...

  • Editorial Commentary: Voriconazole Resistance in Aspergillus fumigatus: Should We Be Concerned? Denning, David W.; Bowyer, Paul // Clinical Infectious Diseases;Aug2013, Vol. 57 Issue 4, p521 

    An introduction is presented in which the editor discusses a report within the issue on topics including voriconazole resistance, allergic bronchopulmonary aspergillosis and antifungal therapy.

  • Voriconazole.  // Reactions Weekly;8/3/2013, Issue 1464, p38 

    The article presents a case study about the exacerbation of myasthenia gravis in a 52-year-old woman after receiving voriconazole for pulmonary aspergillosis.

  • Voriconazole.  // Reactions Weekly;8/1/2013, Issue 1463, p38 

    The article presents a case study of a 47-year old woman who developed insomnia and heavy head feeling during treatment with voriconazole for aspergilloma.

  • An Unusual Case of Pulmonary Invasive Aspergillosis and Aspergilloma Cured with Voriconazole in a Patient with Cystic Fibrosis. Chow, Laura; Brown, Neil E.; Kunimoto, Dennis // Clinical Infectious Diseases;11/1/2002, Vol. 35 Issue 9, pe106 

    The development of pulmonary aspergilloma and invasive aspergillosis is a rare complication of cystic fibrosis. We describe a 29-year-old patient with cystic fibrosis who had invasive pulmonary aspergillosis that was not cured by amphotericin B, liposomal amphotericin B, or itraconazole. This...

  • Peroral Amphotericin B Polymer Nanoparticles Lead to Comparable or Superior In Vivo Antifungal Activity to That of Intravenous Ambisome or Fungizone. Italia, Jagdishbhai L.; Sharp, Andrew; Carter, Katharine C.; Warn, Peter; Kumar, M. N. V. Ravi // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Background: Despite advances in the treatment, the morbidity and mortality rate associated with invasive aspergillosis remains unacceptably high (70-90%) in immunocompromised patients. Amphotericin B (AMB), a polyene antibiotic with broad spectrum antifungal activity appears to be a choice of...

  • Activity and Safety of Inhaled Itraconazole Nanosuspension in a Model Pulmonary Aspergillus fumigatus Infection in Inoculated Young Quails. Wlaź, Piotr; Knaga, Sebastian; Kasperek, Kornel; Wlaź, Aleksandra; Poleszak, Ewa; Jeżewska-Witkowska, Grażyna; Winiarczyk, Stanisław; Wyska, Elżbieta; Heinekamp, Thorsten; Rundfeldt, Chris // Mycopathologia;Aug2015, Vol. 180 Issue 1/2, p35 

    Pulmonary aspergillosis is frequently reported in parrots, falcons, and other birds held in captivity. Inhalation is the main route of infection for Aspergillus fumigatus, resulting in both acute and chronic disease conditions. Itraconazole (ITRA) is an antifungal commonly used in birds, but its...

  • Antifungal Combination Therapy for Invasive Aspergillosis. Martín-Peña, Almudena; Aguilar-Guisado, Manuela; Espigado, Ildefonso; Cisneros, José Miguel // Clinical Infectious Diseases;Nov2014, Vol. 59 Issue 10, p1437 

    Antifungal combined therapy against invasive aspergillosis in primary and salvage therapy has been widespread in recent years, despite limited data supporting its efficacy. The available information is analyzed and our viewpoint on this topic is discussed.The outcome of invasive aspergillosis...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics